Education
About Us
Working with TipRanks
Follow Us
Mangalam Drugs & Organics Ltd. (IN:MANGALAM)
:MANGALAM
MANGALAM Stock Chart & Stats
₹30.40
-₹1.02(-0.89%)
At close: 4:00 PM EST
₹30.40
-₹1.02(-0.89%)
Day’s Range― - ―
52-Week Range₹22.70 - ₹94.80
Previous CloseN/A
Volume15.57K
Average Volume (3M)5.11K
Market Cap
₹491.63M
Enterprise Value₹1.40B
Total Cash (Recent Filing)₹96.75M
Total Debt (Recent Filing)₹949.21M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
May 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.21
Shares Outstanding15,828,248
10 Day Avg. Volume11,101
30 Day Avg. Volume5,111
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)0.84
Price to Sales (P/S)0.39
P/FCF Ratio5.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manageable Leverage And Balanced Balance SheetA balanced capital structure and consistent shareholders' equity provide durable financial stability. Manageable leverage increases the company's ability to absorb cyclical downturns, access financing on reasonable terms, and preserve operational flexibility over the next 2–6 months.
Improving Operating Cash Flow And Cash GenerationImproving operating cash flow and a strong OCF-to-net-income ratio reflect durable cash conversion from core operations. Better cash generation supports working capital needs, debt servicing and targeted reinvestment, enhancing operational resilience over a multi-month horizon.
B2B Specialty Chemicals And API Manufacturing With Domestic And Export ChannelsA B2B focus on specialty chemicals and APIs exposes the company to structurally steady pharma and industrial demand, with diversified domestic and export channels. This business model supports repeat orders, quality-driven barriers to entry, and steady multi-month revenue corridors.
Bears Say
Declining Revenue And Contracting MarginsMaterial revenue decline and margin compression reduce operating leverage and long-term profitability. Persisting lower sales and squeezed margins will weaken cash flows, limit reinvestment capacity, and raise execution risk over the next several months.
Inconsistent And Negative Free Cash Flow In Several PeriodsIntermittent negative free cash flow constrains the firm's ability to fund capex, pay down debt, or return capital without external financing. Over a 2–6 month horizon this increases financing flexibility risk and could force trade-offs between growth and balance-sheet repair.
Rising Total Debt Amid Weakening Top-lineA rising debt level alongside falling revenue elevates leverage and refinancing risk. If weaker sales continue, interest burdens could erode free cash flow and limit strategic options, making the business more vulnerable to external shocks over the medium term.
Mangalam Drugs & Organics Ltd. News
MANGALAM FAQ
What was Mangalam Drugs & Organics Ltd.’s price range in the past 12 months?
Mangalam Drugs & Organics Ltd. lowest stock price was ₹22.70 and its highest was ₹94.80 in the past 12 months.
What is Mangalam Drugs & Organics Ltd.’s market cap?
Mangalam Drugs & Organics Ltd.’s market cap is ₹491.63M.
When is Mangalam Drugs & Organics Ltd.’s upcoming earnings report date?
Mangalam Drugs & Organics Ltd.’s upcoming earnings report date is May 27, 2026 which is in 69 days.
How were Mangalam Drugs & Organics Ltd.’s earnings last quarter?
Mangalam Drugs & Organics Ltd. released its earnings results on Jan 15, 2026. The company reported -₹6.214 earnings per share for the quarter, missing the consensus estimate of N/A by -₹6.214.
Is Mangalam Drugs & Organics Ltd. overvalued?
According to Wall Street analysts Mangalam Drugs & Organics Ltd.’s price is currently Overvalued.
Does Mangalam Drugs & Organics Ltd. pay dividends?
Mangalam Drugs & Organics Ltd. pays a Notavailable dividend of ₹0.5 which represents an annual dividend yield of N/A. See more information on Mangalam Drugs & Organics Ltd. dividends here
What is Mangalam Drugs & Organics Ltd.’s EPS estimate?
Mangalam Drugs & Organics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mangalam Drugs & Organics Ltd. have?
Mangalam Drugs & Organics Ltd. has 15,828,248 shares outstanding.
What happened to Mangalam Drugs & Organics Ltd.’s price movement after its last earnings report?
Mangalam Drugs & Organics Ltd. reported an EPS of -₹6.214 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Mangalam Drugs & Organics Ltd.?
Currently, no hedge funds are holding shares in IN:MANGALAM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mangalam Drugs & Organics Ltd.
Mangalam Drugs & Organics Limited manufactures and sells drugs, medicines, and allied products in India and internationally. It offers a range of active pharmaceutical ingredients, intermediates, and specialty chemicals, as well as impurities for use in anti-malarial, analgesic/anti-inflammatory, anti-hypertensive, and anti-retroviral applications. The company was incorporated in 1972 and is based in Mumbai, India.
Technical Analysis
Bhageria Industries Ltd.
―
Ganesh Benzoplast Limited
―
HP Adhesives Ltd.
―
Khaitan Chemicals & Fertilizers Ltd.
―
Mangalam Organics Ltd
―